Showing 1281-1290 of 1478 results for "".
- ISDIN Launches in the UShttps://practicaldermatology.com/news/isdin-launches-in-the-us/2458501/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. ISDIN’s portfolio of over-the-counter products target
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),
- The La Roche-Posay North American Foundation Awards 2016 Grant Winnershttps://practicaldermatology.com/news/the-la-roche-posay-north-american-foundation-awards-2016-grant-winners/2458530/Committed to working alongside dermatologists, La Roche-Posay's North American Fondation encourages residents, fellows and practitioners with at least two years beyond training to develop innovative programs. The brand and a board of certified dermatologists awards two to three w
- Preston Romm Joins Suneva Medical As Chief Operating Officerhttps://practicaldermatology.com/news/preston-romm-joins-suneva-medical-as-chief-operating-officer/2458528/Suneva Medical Inc. appointed Preston Romm to chief operating officer (COO). Romm joins Suneva Medical with more than 30 years of experience and will be responsible for leading the company's sales, marketing and operations. Previously serving as president of Oba
- Dermatologist Swaps His Scalpel for a Penhttps://practicaldermatology.com/news/dermatologist-swaps-his-scalpel-for-a-pen/2458535/Steven M. Hacker, MD, a Delray Beach dermatologist and author, has released his debut novel. "The Caduceus and The Swastika". The thriller tells a frightening but endearing story of what happened to a group of medical students when Nazi's became medical professors and began a
- Solta Medical Launches Consumer Campaign to Empower LGBTQ Communityhttps://practicaldermatology.com/news/solta-medical-launches-consumer-campaign-to-empower-lgbtq-community/2458538/Solta Medical, a division of Valeant Pharmaceuticals North America LLC, is supporting the LGBTQ community through a focused consumer campaign that will help shed one more layer to reveal one’s true self. In addition, Solta Medical was the exclusive medical aesthetic category sponsor of the
- Kate Bosworth Partners with Allergan for ACZONE® Gel, 7.5% Launchhttps://practicaldermatology.com/news/kate-bosworth-partners-with-allergan-for-aczone-gel-75-launch/2458540/Actress, producer and model Kate Bosworth is the new face of Allergan plc’s ACZONE® (dapsone) Gel, 7.5%. ACZONE® Gel, 7.5% is a once-a-day prescription topical treatment for acne in patients 12 years of age and older. It was approved
- Dermira's DRM04 Shows Promise for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-drm04-shows-promise-for-primary-axillary-hyperhidrosis/2458543/Dermira’s DRM04 may help put the brakes on primary axillary hyperhidrosis, according to topline results from two Phase 3 trials. Based on the results of these trials, Dermira plans to submit a New Drug Application to the US Food and Drug Administ
- Sernivo Spray Hits Pharmacy Shelveshttps://practicaldermatology.com/news/sernivo-spray-hits-pharmacy-shelves/2458544/Sernivo™ Spray for psoriasis is officially available. Dr. Reddy’s Laboratories’ US subsidiary, Promius Pharma, LLC, U.S. Sernivo™ Spray (betamethasone dipropionate) 0.05% was approved by the Food and Drug Administration (F
- FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythemahttps://practicaldermatology.com/news/fda-accepts-allergans-nda-filing-for-oxymetazoline-hci-cream-10/2458553/The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan expects the Prescription Drug User Fee